Aidian Oy

19/03/2026

Colorectal cancer is the third most common cancer and the second leading cause of cancer-related deaths worldwide. Although the incidence is highest among people over 50 years of age, it is rising among younger adults.

Early detection of plays a crucial role – it supports prevention, enables timely treatment, and significantly increases the chance of survival. Regular screenings are an effective way to detect colorectal cancer early.

Faecal immunochemical testing ( ) is an effective tool for both screening and symptomatic assessments. Quantitative FIT tests, such as the QuikRead go iFOBT, detect haemoglobin originating from occult blood in stool samples when there is excess bleeding from the lower gastrointestinal tract. A faecal occult blood result helps triage patients for further examination, such as colonoscopy. 🩺

Visit our website to learn more:
➡️ https://www.aidian.eu/news/colorectal-cancer-awareness-month-2026

Join us in raising awareness for colorectal cancer 🎗️🌍

08/03/2026

Happy International Women’s Day! 🌹

Today, we celebrate women around the world – and the incredible women who shape our company every day. At Aidian, equality is a commitment for us. We monitor and evaluate our progress annually, making improvements wherever needed. A thriving and innovative workplace is built on the foundations of diversity, inclusivity, and equality.

We’re proud to recognize the women who shape and bring their skills and expertise to all that we do. In 2025, women represented 62% of our personnel, contributing their expertise across our organization.

Join us in celebrating women who inspire progress every day! 💜

05/03/2026

Join us in raising awareness for Colorectal Cancer 🎗️🌍

Colorectal cancer is the third most common cancer worldwide. Although the risk of increases with age, incidence has also been rising among younger adults.

Early detection plays a crucial role – it supports prevention, enables timely treatment, and significantly increases the chance of survival. Regular screenings are an effective way to detect colorectal cancer early.

Faecal immunochemical tests ( ), such as QuikRead go iFOBT, offer a simple method to detect excess bleeding from the lower gastrointestinal tract and to help identify those who may need further examination. 🩺 The test can be used in routine physical examinations and in screening programmes for colorectal cancer.

Visit our website to learn more:
https://www.aidian.eu/news/colorectal-cancer-awareness-month-2026

Join us in raising awareness and highlighting the importance of early detection. 🎗️

19/02/2026

New colleague! We are excited to share that Rina Wahlroos has joined Aidian as our Vice President, Quality and Regulatory Compliance.

With more than 20 years of experience in diagnostics and life sciences, Rina brings deep expertise in global quality systems, regulatory requirements, organizational development, and leading change. Her background at Thermo Fisher Scientific and PerkinElmer has equipped her to drive complex transformation initiatives and strengthen people‑focused leadership.

We look forward to seeing how Rina’s deep expertise, forward‑looking mindset, and commitment to continuous improvement will contribute to Aidian’s next chapter.

Join us in welcoming Rina to the Aidian team! 💙

➡️ https://www.aidian.eu/news/aidian-welcomes-rina-wahlroos-as-its-new-vp-quality-and-regulatory-compliance

13/02/2026

Aidian appoints Torben Nielsen as its new CEO

We are pleased to announce the appointment of Torben Nielsen as the new CEO of Aidian. Torben Nielsen, currently CEO and Group President of Boule Diagnostics, will start in his new position no later than June 2026. Torben is highly experienced in the healthcare, diagnostics, and medical technology field, having held senior executive roles at Radiometer, Envista Holdings, and Boule Diagnostics. We are excited to welcome Torben to Aidian as he takes on the responsibility of leading our company forward and supporting our continued growth.

Visit our website for the full announcement.

➡️ https://www.aidian.eu/news/aidian-appoints-torben-nielsen-as-its-new-ceo

05/02/2026

Labquality Days 2026 is here! ❄

📍🗓️ Visit our booth at taking place at Messukeskus in Helsinki on 5–6 February. Come meet our team and discover the QuikRead go Plus Instrument for point‑of‑care testing!

//

Lämpimästi tervetuloa tapaamaan meitä osastollemme Labquality Days -tapahtumassa Messukeskuksessa 5.-6. helmikuuta 👋 Tule juttelemaan tiimimme kanssa ja tutustumaan QuikRead go Plus -laitteeseen!

04/02/2026

📅 Today February 4th is World Cancer Day, a global health awareness day aiming to raise awareness about cancer and encourage its prevention.

💡Colorectal cancer is the third most common cancer and the second most common cancer-related cause of death worldwide. Early detection can significantly increase the chance of survival, and screening programs have been shown to reduce both incidence and mortality.

At Aidian, we support healthcare professionals with reliable diagnostic tools such as QuikRead go iFOBT – a point-of-care FIT test that provides fast, quantitative results to aid in clinical decision-making.

Visit our website to learn more:
➡️ https://www.aidian.eu/news/february-4th-2026-is-world-cancer-day

Colorectal cancer is the third most common cancer worldwide. Early detection can significantly increase the chance of survival.

21/01/2026

Meet us at Labquality Days 2026!

📍🗓️ Come and meet our team at Messukeskus, Helsinki, on 5–6 February and discover our point‑of‑care testing solutions.

Labquality Days is one of Northern Europe's largest congresses focusing on quality in laboratory medicine and health technology. Stop by our booth – we are excited to connect! 👋

//

Nähdään Labquality Days 2026 -tapahtumassa!

📍🗓️ Tule tapaamaan tiimiämme Messukeskukseen Helsinkiin 5.–6. helmikuuta ja tutustu vieritestauksen ratkaisuihimme.

Labquality Days on yksi Pohjois-Euroopan suurimmista laboratoriolääketieteeseen ja terveysteknologiaan keskittyvistä tapahtumista. Tervetuloa ständillemme! 👋

18/12/2025

As the year 2025 soon comes to a close, we want to express our gratitude to all our customers, business partners, and colleagues. Thank you for your continued trust and collaboration. 💙

We wish you and your loved ones a peaceful holiday season and a happy and healthy New Year 2026!

Warm regards from all of us at Aidian ✨

27/11/2025

Warsaw Medical Expo is here!

Visit our booth B1.16 at the Warsaw Medical Expo taking place at Ptak Warsaw Expo in Warsaw. Come and discover the QuikRead go Plus Instrument – an easy-to-use in vitro diagnostic system that delivers accurate results in minutes at the point of care.

is live until 27 November – if you haven't already visited our booth, make sure to stop by today. We look forward to meeting you!

Do zobaczenia! 👋

24/11/2025

Test before prescribing 💊

Antibiotic-resistant bacteria pose a growing worldwide threat. According to WHO’s Global Antibiotic Resistance Surveillance Report 2025, approximately 1 in 6 laboratory-confirmed bacterial infections worldwide in 2023 were caused by bacteria resistant to antibiotics. The report also indicates that, for urinary tract infections (UTIs) caused by E. coli and K. pneumoniae, resistance to commonly prescribed antibiotics generally exceeded 30% worldwide.

Reducing unnecessary antibiotic use is crucial to prevent the development of . Uricult is a culture based dipslide method used as an aid in the diagnosis of UTIs. Uricult, Uricult Plus, and Uricult Trio help to narrow down the infecting bacteria for making an informed treatment decision.

Learn more from our website:
👉 https://www.aidian.eu/microbiology/uricult/uricult-tests

20/11/2025

Antibiotic-resistant bacteria: a growing worldwide threat

Antimicrobial resistance ( ), also known as the , is one of the top global public health and development threats. According to a recently published report by the World Health Organization (WHO), in 2023 approximately 1 in 6 laboratory-confirmed bacterial infections worldwide were caused by bacteria resistant to antibiotics.

In healthcare, optimising antibiotic use is critical to prevent further development of AMR: decreasing antibiotic overuse and providing antibiotics to those patients who benefit from the treatment.

C-reactive protein ( ) point-of-care testing ( ) is considered as a key player in healthcare to guide rational use of antibiotics and prevent the development of . CRP POCT has several benefits in management of patients with respiratory tract infections in primary care:

✅ provides immediate results for faster decisions
✅ increases diagnostic certainty for physicians
✅ targets antibiotic use for those patients who truly benefit from the treatment
✅ reduces antibiotic use by approximately 23% in acute respiratory tract infections

The choices we make today in managing infections have a profound impact on our global health in the future. Let’s keep pushing for smarter and evidence-based use of antibiotics in healthcare!

👉 Learn more on our website:
https://www.aidian.eu/news/world-amr-awareness-week-waaw-is-observed-18-24-november